A Pharmaceuticals (API and Intermediary Manufacturing) entity from India is looking to sellout.
BUSINESS BRIEF
- The company is an Intermediates & API manufacturer, operating since 2008.
- It has two factories with an overall capacity of over 500 KL.
- Key Clientele: OLON, MOEHS, KOLON, VALEANT, TEVA, AUROBINDO, MYLAN, SUN PHARMA, SOLARA ACTIVE PHARMA SCIENCES, GLENMARK LIFE SCIENCES, NICHOLAS PIRAMAL and many more.
- Expertise in handling critical reactions like Cyanation, Hydrogenation, Bromination, Grignard, High vacuum
distillation, Cryogenic reactions, and more. - Complete backward integration and suitable capability to handle both low-volume and high-volume
products at the commercial level. - In the process of increasing the production capacity by 300 KL. Currently, the company has taken an organic expansion of over 130-150KL of capacity in its Choutuppal unit which is expected to get operationalized during second half of FY22-23.
Key Highlights:
-
Total land extent: 11 Acres+
-
Assets Quality: Best Infrastructure
-
Certification: US FDA approved & others
Expertise:
- Quality Policy- The company is committed to practicing the best quality standards in research &
development and manufacturing of pharmaceutical products through periodic review systems. - Product Focus- The company is very keen on product selection and commercialization
based on the market demand for the product and its uniqueness. - Spread- One of the core competencies was to reach different customers and markets to understand
their needs and cater to them aptly. - Speed: Well known in the industry for being swift in development, optimization,
validation and commercialization of new products/projects. - R&D: Well-equipped and dedicated Research and Development lab consisting of professional scientists & chemists with strong knowledge of chemistry.
- Integration: Company's backward integration with their KSM & intermediate manufacturing
enables cost competence, sustainability, better supply chain control, and strict quality standards
adherence.
Disclaimer:
-For further information, the promoter requires the signing of an LOI
-Papers & Financials: Ready in place & can be checked at the owner's office only.
Proposal
Industry
Pharmaceuticals
Sub Industry
API
Deal Size
INR 400 - 450 Cr
Motives For Sellout
Raising Capital
Business Operation Information
Industry
Pharmaceuticals
Sub-Industry
API
Type
Location
Major Products
Major Customers
Financial Information |
2019 (in Cr) | 2020 (in Cr) | 2021 (in Cr) | 2022 (in Cr) |
---|---|---|---|---|
Sales |
INR 66.1 Cr | INR 92.5 Cr | INR 113.1 Cr | N.D |
EBITDA |
N.D | N.D | N.D | N.D |
PAT |
N.D | N.D | N.D | N.D |
TOTAL DEBT |
N.D | N.D | N.D | N.D |